Cubist seeks expanded label for Cubicin

Touting a late-stage trial that highlights the effectiveness of Cubicin in reducing heart valve and blood infections caused by Staph bacteria, Cubist Pharmaceuticals says it will ask the FDA for an accelerated review to expand its use. Cubicin is currently approved to prevent skin infections caused by Staph bacteria.

- read this article from the AP for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.